Trial Site News
Last 10 Stories
- 2022-2023 Flu Vaccine 37% VE Against Hospitalization & Varies by Age & Flu Strain: CDC IVY Network
- Merck Using RNA-Based Vaccine to Vaccinate Pigs Against Swine Flu
- German Researchers Identify Biomarkers Pointing as to Who Can Benefit with CAR T Cell Therapies in Bone Marrow Tumors
- CDC & Colleagues Paper: Safety Monitoring Infrastructure & Processes Worked Perfectly Fine During COVID-19 Pandemic
- Breakaway Physician & Surgeon Board Seeks Independence from Declared ‘Monopoly’ Powers of ACGME
- The Poor Relation in Drug R&D—Chemistry, Manufacturing and Controls
- Can AI Save Patient Recruitment? Probably Not But it May Help Improve on the Margins—Key Factor Missing: Trust
- IRB Industry Leaders Advarra and WCG Join with SASI in Support of Site Accreditation
- NIH/NIAID Study Finds Lower Dose of Mpox Vax Safe Plus Generates Six-Week Antibody Response Like Standard Dose
- NIH Developed mAb, Tested at Mali Trial Sites, Shows 77% Effectiveness in Children Against Malaria